Skip to main content

Eva Colas Ortega

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Eva Colas Ortega

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

I am biologist by formation and fully dedicated to endometrial cancer research for the last 16 years. From 2017, I lead my own team in the Group of Biomedical Research in Gynecology (VHIR) and my research focus on the implementation of molecular diagnostics and personalized medicine in gynecology, mainly in endometrial cancer (EC) and endometriosis.
In my career I participated in the development of the first EC patient-derived murine models (PDX), and today, my group owns one of the largest PDX biobanks in Europe, which is used by us, partners and pharma to assess treatments for EC patients. Importantly, I have also grown as a scientist dedicated to biomarker research in gynecological fluids. I worked in the development of the first molecular kit to diagnose EC. Today, I am the European Coordinator of a multicenter study to develop a non-invasive diagnosis of EC (ERA PerMed), and am the founder of a spin-off (MiMARK Diagnostics S.L.) that aims to develop innovative solutions for women health.
As a summary, I have a total of 73 scientific articles with impact factor; 17 of them as senior author; and am inventor of 4 patents. My scientific and leadership capacity is proved by the supervision of 12 doctoral theses, 6 of which have already been defended, two of them awarded. I have participated in 32 competitive research projects, being 13 of them principal investigator, and I am actively participating in national (CIBERONC) and international (ENITEC) cancer networks.
I have been teaching in graduate and master studies for the last 7 years; and I have been on the Steering Committee of the Societat Catalana de Biologia for 10 years.

Projects

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Jaume Reventós Puigjaner
Collaborators: Joan Morote Robles, Inés de Torres Ramirez, Maria Asuncion Perez Benavente, Eva Colas Ortega, Silvia Cabrera Diaz, Antonio Gil Moreno, Rosanna Paciucci Barzanti, Marina Rigau Resina, Carles Xavier Raventós Busquets, Jacques Planas Morin, Anna Santamaria Margalef
Funding agency: Instituto de Salud Carlos III
Funding: 229500
Reference: RD12/0036/0035
Duration: 01/01/2013 - 30/06/2017

Alteraciones moleculares relacionadas con la progresión tumoral en el cáncer de endometrio Numero projecte extern: GCB 110333 REVE

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega, Marta Rebull Santamaria
Funding agency: Asociación Española Contra el Cáncer
Funding: 1200000
Reference: AECC- GCB 110333 REVE
Duration: 01/08/2011 - 28/07/2016

Identification of new molecules and mechanisms of myometrial infiltration and early diagnosis to improve survival in endometrial cancer

IP: Jaume Reventós Puigjaner
Collaborators: Maria Asuncion Perez Benavente, Eva Colas Ortega, Josep Castellví Vives
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 133100
Reference: SAF2011-26548
Duration: 01/01/2012 - 31/12/2014

Ministerio de Ciencia

Valorización de biomarcadores oncológicos para el desarrollo de kits de diagnóstico/pronóstico para el cáncer de próstata y de pulmón

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 210407
Reference: IPT-2011-1569-010000
Duration: 06/09/2011 - 28/02/2014

Ministerio de Ciencia

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Ma Irene Valenzuela Palafoll

Ma Irene Valenzuela Palafoll

Predoctoral researcher
Genetics Medicine
Read more
Verónica Villagrasa Araya

Verónica Villagrasa Araya

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Monica Anglada Baguena

Monica Anglada Baguena

Coordinador/a
Quality, Processes and Document Management
Digital Transformation and Quality Area
Read more
Albert Vilanova Baldellou

Albert Vilanova Baldellou

Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.